MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy
Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori, Michihisa Kono, Masahiro Rokugo, Yuto Baba, Takeo Kosaka, Mototsugu Oya, Justine Jacobi, Mark D. Long, Himisha Beltran, Donald Kufe
Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori, Michihisa Kono, Masahiro Rokugo, Yuto Baba, Takeo Kosaka, Mototsugu Oya, Justine Jacobi, Mark D. Long, Himisha Beltran, Donald Kufe
View: Text | PDF
Research Article Oncology Therapeutics

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy

Abstract

Androgen receptor–positive prostate cancer (PC), castration-resistant prostate cancer (CRPC), and neuroendocrine prostate cancer (NEPC) invariably become resistant to treatment with targeted and cytotoxic agents. Multiple pathways have been identified as being responsible for these pleiotropic mechanisms of resistance. The mucin 1 (MUC1) gene is aberrantly expressed in CRPC/NEPC in association with poor clinical outcomes; however, it is not known if the oncogenic MUC1-C/M1C protein drives treatment resistance. We demonstrated that MUC1-C is necessary for resistance of (i) PC cells to enzalutamide (ENZ) and (ii) CRPC and NEPC cells to docetaxel (DTX). Our results showed that MUC1-C–mediated resistance is conferred by upregulation of aerobic glycolysis and suppression of reactive oxygen species necessary for self-renewal. Dependence of these resistant phenotypes on MUC1-C for the cancer stem cell (CSC) state identified a potential target for treatment. In this regard, we further demonstrated that targeting MUC1-C with an M1C antibody-drug conjugate (ADC) is highly effective in suppressing (i) self-renewal of drug-resistant CRPC/NEPC CSCs and (ii) growth of treatment-emergent NEPC tumor xenografts derived from drug-resistant cells and a patient with refractory disease. These findings uncovered a common MUC1-C–dependent pathway in treatment-resistant CRPC/NEPC progression and identified MUC1-C as a target for their therapy with an M1C ADC.

Authors

Keisuke Shigeta, Tatsuaki Daimon, Hiroshi Hongo, Sheng-Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, Ayako Nakashoji, Atrayee Bhattacharya, Shinkichi Takamori, Michihisa Kono, Masahiro Rokugo, Yuto Baba, Takeo Kosaka, Mototsugu Oya, Justine Jacobi, Mark D. Long, Himisha Beltran, Donald Kufe

×

Figure 3

DU-145-DR cells are dependent on MUC1-C for DTX resistance and self-renewal capacity.

Options: View larger image (or click on image) Download as PowerPoint
DU-145-DR cells are dependent on MUC1-C for DTX resistance and self-rene...
(A) Parental DU-145 and DU-145-DR cells treated with DTX for 3 days were analyzed for cell viability. (B) Heatmap of NE, CSC, and glycolytic gene expression from qRT-PCR analysis of biological triplicates of DU-145 and DU-145-DR cells. (C) Immunoblot analysis of DU-145 and DU-145-DR cell lysates run at different times. (D) DU-145 and DU-145-DR cells were analyzed for colony formation. Representative photomicrographs of stained colonies (left). Results (mean ± SD of 3 determinations) expressed as relative colony number compared with DU-145 cells (assigned a value of 1) (t test; n = 3) (right). (E) DU-145 and DU-145-DR cells were analyzed for tumorsphere formation (t test; n = 3). (F) Immunoblot analysis of lysates from DU-145-DR/tet-MUC1shRNA cells treated with DOX for 7 days run contemporaneously in parallel. (G) DU-145-DR cells expressing tet-MUC1shRNA and/or tet-MUC1-CD vectors treated with vehicle or DOX for 7 days were analyzed for colony formation (t test; n = 3). (H) DU-145-DR cells expressing tet-MUC1shRNA and/or tet-MUC1-CD vectors were treated with vehicle or DOX for 7 days and analyzed for tumorsphere formation (t test; n = 3). (I) Lysates from DU-145-DR cells treated with vehicle or 3 μM GO-203 for 3 days were immunoblotted with antibodies against the indicated proteins run contemporaneously in parallel. (J) DU-145-DR cells treated with vehicle or 3 μM GO-203 for 3 days were analyzed for tumorsphere formation (t test; n = 3). (K) DU-145-DR/tet-MUC1shRNA cells treated with DOX for 7 days and then with DTX for 3 days were analyzed for cell viability. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.